Children as young as 8 years old should be screened for anxiety and those ages 12 and over for depression, according to new recommendations by the government-backed U.S. Preventive Services Task Force (USPSTF).

Katie Couric, award winning journalist and colorectal cancer advocate who normalized talking about colon cancer more than two decades ago, announced she teamed up with Cologuard® maker Exact Sciences to highlight the urgent need for people to get screened.

A little more than a month after Bay Area-based Freenome snagged $300 million in a Series D financing round, the company scored an additional $290 million from an investment made by Swiss pharma giant Roche.

The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.

South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing, with the round led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors.

Routine medical tests critical for detecting and monitoring cancer and other conditions plummeted in the United States since mid-March, as the coronavirus spread and public officials urged residents to stay home, according to a new report by Komodo Health.

Exact Sciences Corp.’s shares shot up as much as 26 percent after announcing that Pfizer Inc. would share marketing expenses and co-promote the company’s stool screening test for colorectal cancer.

As many as 270 women in England may have died prematurely of breast cancer because of an IT failure that led to 450,000 patients missing out on routine screening appointments.

 

Charles River Laboratories, a contract research organization (CRO) with headquarters in Wilmington, Mass., is buying MPI Research for about $800 million.

An influential physician task force backed by the U.S. government is softening its opposition to routine prostate cancer screening.